The condition affecting 1 in 8 women globally has a new name as of May 2026: Polycystic Ovary Syndrome (PCOS) is now Polyendocrine Metabolic Ovarian Syndrome (PMOS). This isn't a simple rebrand. The Lancet published a global consensus backed by 56 medical organizations, including the Endocrine Society, that fundamentally reframes how doctors should understand and treat this condition. The change reflects 14 years of research and input from over 14,300 patients and clinicians worldwide.

Why Did PCOS Need a New Name?

The original name focused on what doctors saw on ultrasound: cysts on the ovaries. But that framing was misleading and harmful. A companion paper published in The Lancet confirmed what clinicians have long suspected: women with this condition do not actually have an increase in abnormal ovarian cysts. The follicles visible on ultrasound are part of normal ovarian function at a particular point in the cycle, not pathological cysts.

This misunderstanding created real problems in clinical practice. Women without visible cysts on ultrasound were sometimes told they couldn't have PCOS, delaying their diagnosis. The ovary-focused name also obscured the metabolic and hormonal drivers of the condition, leading many providers to treat it primarily as a reproductive issue rather than the multi-system endocrine disorder it actually is. Insurance and research funding followed the ovarian framing, which limited the kinds of treatments studied.

What Does the New Name Actually Mean for Treatment?

Each word in "Polyendocrine Metabolic Ovarian Syndrome" matters. "Polyendocrine" means multiple hormones are involved, not just one. Insulin, androgens (testosterone), luteinizing hormone, sex hormone-binding globulin, and others all interact dysfunctionally. "Metabolic" highlights the condition's metabolic core: insulin resistance is the engine driving PMOS for most women who have it.

When the body becomes less responsive to insulin, the pancreas pumps out more insulin to compensate. Those high insulin levels signal the ovaries to produce more testosterone than they should. That excess testosterone is what drives the visible symptoms women experience: irregular menstrual cycles, acne, unwanted hair growth, weight gain that resists typical interventions, and difficulty conceiving.

"There's too much insulin in many women with this condition, and that insulin confuses the ovary to make too much testosterone," explained Dr. Melanie Cree, a pediatric endocrinology expert at the University of Colorado Anschutz and a lead author on the Lancet paper.

Dr. Melanie Cree, Pediatric Endocrinology Expert at University of Colorado Anschutz

The ovaries are still involved in PMOS, producing abnormal hormone levels that affect reproduction. But they're downstream of the metabolic and endocrine drivers, not the source of the problem. This distinction changes the order of operations in treatment.

How Should PMOS Treatment Change?

The old PCOS framework often led with hormonal birth control to manage symptoms. While that can be valid for some women, it doesn't address insulin resistance and in some cases may make it slightly worse. The new PMOS framework prioritizes addressing the metabolic engine first, then layering on other treatments as needed.

• Lifestyle modifications as the foundation: Sleep quality, regular exercise, dietary changes that reduce blood sugar volatility, and stress management are not optional. These form the foundation of treatment, with strong scientific support for their effectiveness.
• Insulin-sensitizing medications: Metformin remains the most-studied option with decades of data. Myo-inositol, typically combined with D-chiro-inositol, has accumulated strong evidence as a comparable alternative with fewer side effects for many women.
• Weight management when relevant: This includes GLP-1 receptor agonists like semaglutide and tirzepatide for women whose PMOS is significantly driven by metabolic dysfunction, though these medications are not yet FDA-approved specifically for PMOS.
• Hormonal support layered on top: Spironolactone for androgen-driven symptoms like acne and unwanted hair, hormonal birth control when contraception is also a goal, or bioidentical hormone replacement therapy in perimenopausal women. These are deployed as part of a larger plan rather than as first-line treatment.

The GLP-1 medications represent an evolving part of the treatment landscape. Semaglutide and tirzepatide are not FDA-approved for PMOS; their approved uses are for type 2 diabetes and chronic weight management. However, for women whose PMOS is significantly weight-driven, off-label use of GLP-1s is growing, and early data shows promise. Insurance coverage remains inconsistent precisely because this isn't a labeled indication.

What Does This Mean If You Already Have a PCOS Diagnosis?

Your diagnosis didn't change on the day of the rename. If you've been told you have PCOS, you still have the same condition; it simply has a new, more accurate name. You don't need new laboratory work or a new diagnostic workup based on the renaming alone.

However, the rename validates a treatment approach that prioritizes metabolic assessment and insulin resistance as the starting point. For women seeking care, this means asking your provider about your insulin levels and metabolic function, not just your reproductive symptoms. The new framework suggests that addressing the metabolic root cause first, rather than jumping to hormonal birth control, may produce better long-term outcomes.

The Endocrine Society and the 55 other organizations behind this change describe the old name as inaccurate, stigmatizing, and a barrier to good care. The new name reflects what science has revealed: PMOS is fundamentally a metabolic and endocrine disorder that happens to affect the ovaries, not the other way around.